LE WE PMID CA
Blinatumomab ttCD1910573Blinatumomab ttCD19

Alemtuzumab ttCD52

Antibodies (bispecific)

Antibodies (therapeutic use)

Bi20 ttCD20

Blinatumomab ttCD19

Catumaxomab ttEpCAM ttCD3 linkerAb

CD19

CD20

CD37

Ertumaxomab ttHER2

Flavopiridole

GA101 ttCD20

Leukemia (chronic lymphatic)

Lumiliximab ttCD23

Ofatumumab ttCD20

TRU016 ttCD37

2010  
1
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
[21317446] Oncotarget 1(7): 472-82 (2010)
2009  
2
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
[20073127] MAbs 1(6): 539-47 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Blinatumomab ttCD19

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia